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Background: EES has been developed in an attempt to improve clinical outcomes.
Meanwhile, the other rapamycin derivatives-eluting stents are worldwide used as well.
Methods: We searched Medline, the Cochrane Library and other internet sources,
without language or date restrictions for articles comparing clinical outcomes between
EES and other derivatives-eluting stents. Safety endpoints were stent thrombosis (ST),
mortality, cardiac death, and myocardial infarction (MI). Efﬁcacy endpoints were
major adverse cardiac event (MACE), target lesion revascularization (TLR) and target
vessel revascularization (TVR).
Results: We identiﬁed 16 randomized controlled trials (n¼23,481) with a weighted
mean follow-up of 18 months. Compared with other rapamycin derivatives-eluting
stents, EES was associated with a signiﬁcant low incidence of deﬁnite ST (relative risk
[RR]: 0.45, 95% conﬁdence interval [CI]: 0.30-0.69; p<0.001), TLR (RR: 0.87; 95%
CI: 0.77-0.99; p¼0.03), and a nonsigniﬁcant trend towards low rate of deﬁnite/
probable ST (RR: 0.75; 95% CI: 0.56-1.01; p¼0.06). EES had similar rates of
mortality (RR: 0.95; 95% CI: 0.82-1.09; p¼0.45), MI (RR: 0.95; 95% CI: 0.82-1.10;
p¼0.43), MACE (RR: 0.94; 95% CI: 0.87-1.02; p¼0.35) compared with Non-EES
group. Based on the stratiﬁed analyses of the included trials, the treatment effect on
deﬁnite ST was not statistical signiﬁcance between 2 groups within 1 year follow-up
(p¼0.07), while EES was related to a signiﬁcant low rate of deﬁnite ST compared with
either zotarolimus-eluting stent or sirolimus-eluting stent (p¼0.012, p¼0.006,
respectively).
Conclusions: EES is associated with a signiﬁcant reduction of deﬁnite ST and TLR
for treating patients with coronary artery disease, compared with a pooled group of
other rapamycin derivatives-eluting stents. Longer term of follow-up are warranted to
conﬁrm the safety and efﬁcacy beneﬁts of EES.
TCT-838
Management of Drug Eluting Stent In-Stent Restenosis: A Systematic Review
and Meta-Analysis
Sachin S. Goel1, Rama Dilip Gajulapalli2, Ganesh Athappan3, Supriya Gupta2,
Stephen Ellis2, E. Murat Tuzcu4, Samir Kapadia5
1Cleveland Clinic Foundation, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH,
3Metrohealth Medical Center/Case Western Reserve University, Cleveland, OH,
4Cleveland Clinic Foundation, Cleveland, Ohio, 5Cleveland Clinic, Cleveland, United
States
Background: The optimal treatment of drug eluting stent in-stent restenosis (DES
ISR) is unclear. We performed a meta-analysis of published studies to compare the
outcomes of treatment of DES ISR using DES, drug eluting balloon (DEB) or balloon
angioplasty (BA).
Methods: Eligible studies were identiﬁed using MEDLINE search and proceedings of
international meetings. Outcomes studied include major adverse cardiac events
(MACE), target lesion revascularization (TLR), target vessel revascularization (TVR),
myocardial infarction (MI), stent thrombosis (ST) and mortality.
Results: 25 single arm and 13 comparative studies with a total of 7,474 patients with
DES ISR were included in this analysis. Follow up ranged from 0.5-3.5 years (mean
1.4 years). TLR rate was signiﬁcantly lower in the DES (Odds ratio [OR] 0.50, 95%
conﬁdence interval [CI] 0.36-0.69) and DEB (OR 0.31, 95% CI 0.18-0.55) groups
compared to BA alone. Similarly, TVR rate was signiﬁcantly lower in the DES (OR
0.55, 95% CI 0.39-0.77) and DEB (OR 0.32, 95% CI 0.18-0.58) groups compared to
BA. All other outcomes were similar between the DES/POBA and DEB/POBA
comparisons. There was only one study comparing DES with DEB which showed
similar outcomes. On subgroup analysis of reference vessel diameter < or > 2.75 mm,
TLR was signiﬁcantly lower in the DES group compared to POBA for small as well as
larger vessels. Pooled TLR rate was lowest in the DES groupConclusions: Treatment of DES ISR with DES or DEB is associated with a reduction
in the risk of TLR and TVR compared to BA alone. Randomized trials are needed to
compare DES and DEB in the management of DES ISR.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-839
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Background: Trans-aortic valve replacement (TAVR) has been proven a safe alter-
native for surgery and medical therapy in high risk and;or inoperable patients with
aortic stenosis. Transfemoral and transapical accesses were the initially evaluated but
the subclavian has emerged as an alternative. As the data regarding the subclavian
access safety is still scarce we aimed to compare it to the prior alternatives in a meta-
analysis.
Methods: We searched PubMed, EMBASE, and Cochrane databases from 1966
through May 2013 for studies comparing subclavian (SC) vs. transfemoral (TF) and or
transapical accesses (TA). We evaluated 30 days mortality, stroke, vascular compli-
cations, pacemaker need, and dialysis requirement rates. We analyzed the data with
RevMan 5.2 with ﬁxed effect if P>0.1 and I2<40%, and random effect otherwise.
Results: Out of 204 articles, 5 articles presented the studied data and were included in
the analysis. The pooled data provided a total of 3855 patients being 3201 TF, 654 TA
and 630 SC. As demonstrate in ﬁgure 1 SC had 30 days mortality comparable to TF
(A), TA (B) and their grouping (C). Similar results were found in stroke (CI 0.42-
4.43), vascular complications (CI 0.62-7.25) and pacemaker requirement (CI 0.43-
1.36). When compared only to TF the procedure failure and dialysis requirement were
again similar (CI) and (CI).Conclusions: The subclavian access seems to be a safe alternative in TAVR. Larger
studies are needed to validate this our ﬁndings.
TCT-840
Clinical outcomes of patients treated with Nobori biolimus-eluting stent: meta-
analysis of randomized trials
Salvatore Cassese1, Massimiliano Fusaro1, Robert Byrne1, Antoinette de Waha1,
Tomohisa Tada1, Michael Joner1, Petra Hoppmann2, Karl-Ludwig Laugwitz2,
Heribert Schunkert1, Adnan Kastrati1
1Deutsches Herzzentrum, Munich, Germany, 21. Medizinische Klinik, Klinikum rechts
der Isar, Munich, Germany
Background: The Nobori is a new-generation, biodegradable-polymer coated, BES
that has recently been investigated in several randomized trials with inconsistent
results
Methods: We undertook a meta-analysis of randomized trials investigating Nobori
BES versus other DES. Primary efﬁcacy and safety outcomes were target lesion
revascularization (TLR) and deﬁnite/probable stent thrombosis (ST), respectively.
Secondary outcomes were the composite of cardiac death/myocardial infarction (MI)/
target vessel revascularization (TVR), MI and death.
Results: A total of 9,114 PCI-patients randomly received Nobori BES (n¼ 5,080) or
other DES (n¼ 4,034). This latter group comprised patients receiving everolimus- (n¼
2,533), sirolimus- (n¼ 1,376) or paclitaxel-eluting stents (n¼ 125). Median follow-up
was 11 months [interquartile range 9-12]. The Nobori BES versus other DES showed
comparable risk of TLR (odds ratio [95% Conﬁdence interval]¼ 0.91 [0.57–1.46], p¼
0.71). There was signiﬁcant heterogeneity across trials due to signiﬁcant lower TLR
risk with Nobori BES versus paclitaxel-eluting stent (0.32 [0.10–0.98], p¼ 0.046; p
for interaction¼ 0.009). Nobori BES versus other DES showed comparable risk of
deﬁnite/probable ST (1.40 [0.66–2.97], p¼ 0.39), cardiac death/MI/TVR (1.05 [0.88–
1.25], p¼ 0.59), MI (1.13 [0.87–1.48], p¼ 0.37) and death (1.09 [0.81–1.48], p¼
0.56).
Conclusions: Nobori BES has comparable efﬁcacy with other limus-eluting stents and
superior efﬁcacy in comparison with paclitaxel-eluting stent at 1-year follow-up.
There is no difference in terms of safety proﬁle between these stent platforms.acts/POSTER/Meta-Analyses and Reviews B253
